ABSTRACT
INTRODUCTION
Antifibrinolytic agents are widely used in cardiac surgery during the peri-operative period to reduce blood loss and promote blood conservation. However, the BART trial in 2008 (Blood Conservation Using Antifibrinolytics in Randomized Trial) showed that patients receiving aprotinin had an increase in mortality and renal dysfunction. 1 Consequently, tranexamic acid (TXA), the other antifibrinolytic agent commonly used in Canada, became the agent of choice to reduce blood loss in cardiac surgery with cardiopulmonary bypass (CPB).
In the intervening years, several studies have reported an increase incidence of postoperative seizures associated with the use of TXA in cardiac surgery patients. Suspected risk factors for this outcome are high dose TXA (>100 mg/kg), patients with pre-operative renal failure, older patients and patients undergoing open-heart surgery. 2, 3 High dose TXA appears to be a main factor responsible for seizures in several retrospective studies. [2] [3] [4] [5] [6] [7] [8] [9] Between the years 2006 and 2014, two doses of TXA were commonly used in our centre; a high dose or a low dose according to the anesthesiologist in charge of the case. So far, no study has compared low dose versus high dose TXA for the incidence of postoperative seizures. Accordingly, we hypothesized that administration of lower doses of TXA would result in a lower incidence of postoperative seizures after cardiac surgery with CBP. Therefore we retrospectively compared the incidence of seizures between the two different doses of TXA used in our institution. We also conducted a comprehensive chart review of all patients with postoperative seizures in order to find differences in demographics, comorbidities, pharmacologic profiles, blood loss, transfusions, or other intraoperative or post-operative factors between the low and high dose TXA.
METHODS
The study was approved by the Institutional Review Board of our Institution as a single center retrospective analysis of the data on every adult undergoing cardiac surgery between April 2006 and April 2014. The requirement for written informed consent was waived by the IRB. We reviewed the files of every patient in whom a seizure was documented in the surgical intensive care unit (SICU) during the post-operative period. These patients were identified using the radiology database by reviewing all reports of cerebral computerized tomography (CT scan) performed for patients who sustained a convulsive episode in the SICU. In our institution all patients who suffer a witnessed convulsion systematically undergo a cerebral CT scan. We excluded patients with a new ischemic injury as confirmed by the cerebral CT scans. Data related to the antifibrinolytic used, low or high dose TXA or aprotinin were retrieved from the perfusionists database. The types of surgery performed between 2006 and 2014 were identified using the operating room database. Patients were divided in groups according to the type of antifibrinolytic received: aprotinin, low dose TXA, high dose TXA or no antifibrinolytic.
Aprotinin was given according to the Hammersmith protocol, as a bolus of 2 X 10 6 KIU administered just prior to initiation of CPB, followed by a continuous infusion of 0.5 X 10 6 KIU until chest closure, 2 X 10 6 KIU was added to the CPB prime. 10 Two doses of TXA were given; a high dose (30 mg/kg bolus and infusion of 15 mg/kg/h and 2 mg/kg in CPB priming), 1 and a low dose (1000 mg bolus and 400 mg/h infusion, 500 mg in CPB priming).
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For some patients, the dose of TXA was different from the high and low dose (other dose). In patients with low and high doses of TXA, the infusion was stopped at the end of CPB.
A comprehensive review of medical records was undertaken for all patients who presented a seizure in the SICU. Demographic, laboratory results and medications were reviewed.
Demographic data included: sex, age, weight and height of the patients. Co-morbidities were noted, including hypertension, dyslipidemia, diabetes, chronic renal insufficiency, chronic obstructive pulmonary disease, previous myocardial infarction and stroke. The following clinical data were collected: cardiopulmonary bypass (CPB) time, aortic clamping time, use of deep hypothermic circulatory arrest (DHCA), type of surgery (coronary artery bypass graft surgery, valvular surgery, or combined surgery), minimal temperature during CPB, inotropic and vasopressor support at 24 hr after the surgery, intra-aortic balloon pump use, intra-operative and post-operative blood loss, highest post-operative temperature during the day of the seizure, length of SICU and total hospital stay, time of endotracheal intubation in the SICU and in-hospital death. Laboratory results included head CT scans following the convulsive episodes and basic laboratory results obtained the day of the convulsive seizures, plasma hemoglobin, potassium, glucose and creatinine levels.
Statistical Analysis
The incidence of postoperative seizures for various subgroups of subjects (type and dosage of antifibrinolytic and type of surgery) is presented as frequency (percentage). The comparison between the low and high TXA doses in terms of this incidence, which is the main objective of this study, was done using a chi-squared test, and a risk ratio was calculated. The incidence of seizures for other subgroups of subjects was also compared using the same statistical test. The main characteristics (demographics, comorbidities, pharmacologic profiles, blood loss, and transfusion) of the low and high TXA groups in patients experiencing a postoperative seizure were presented and groups were compared using a chi-squared test as for the main endpoint for categorical variables. Continuous variables with normal distribution was presented using mean ± standard deviation and groups were compared using Student's T test. Otherwise, median (first, third quartile) and non-parametric Mann-Whitney-Wilcoxon test were used. A p value less than 0.05 was considered statistically significant. Adjustment for multiple comparison was not done in this exploratory study. Statistical analysis was performed using SAS 9.4 (SAS Institute gave us the opportunity to compare low and high doses of tranexamic acid on the incidence of seizures. All possible cases were used to provide maximum power to predict a difference.
RESULTS
Between April 2006 and April 2014, 12195 patients underwent cardiac surgery at our institution.
Of these patients, we identified 98 patients (0.8%) who were investigated using a head CT scan for a seizure occurring while they were in the SICU. Of these 98 patients, seventeen were excluded from the analysis because the CT scan showed a new ischemic injury (7 in the first CT scan and 10 in the second CT scan). The effect of the dose of TXA and type of surgery on the incidence of non-ischemic seizures are reported in Tables 1 and 2 Table 1) . Open chamber cardiac surgery was also linked to a higher incidence of seizures when compared to coronary artery bypass (80/6662 (1.20%) vs 11/5533 (0.20%), p0.0001) ( Table 1) .
When patients with a new ischemic injury after the second CT scan were excluded, we observed that higher doses of TXA was still associated with more seizures than aprotinin (32/2190 vs 3/1550 patients, p< 0.0001), however, no significant difference was observed between lower doses of TXA and aprotinin (38/7452 vs 3/1550, p = 0.0924). Table 2 shows the effect of the TXA doses and type of surgery when patients with the second head CT-scan with ischemic injury were excluded. Schematic representation of type of type and dose of antifibrinolytic are shown in Figure 1 . Table 3 presents the characteristics of the patients in the non-ischemic seizures group who received both high and low dose TXA. No differences were found between either groups with respect to demographic data, comorbidities, intra-operative blood loss (450 (250,750) ml vs 450 (225,600) ml, p = 0.3831), post-operative blood loss (1268 (820,1805) ml vs 1305 (430, 1990) ml, p = 0.5814) and total perioperative red blood cell use (4(2,9) unit vs 3(2,6) units, p = 0.2688) ( Table 3 ). However, we measured a higher level of creatinine on the day of the seizure in the low dose TXA group (140.6 ± 56.9 mmol/L vs 114.4 ± 38.7 mmol/L, p = 0.0156) and more patients had a deep hypothermic circulatory arrest (DHCA) during the surgery in the low dose TXA regimen (19.6% vs 5.0%, p = 0.0409) ( Table 3) .
DISCUSSION
Tranexamic acid is widely used to reduce blood loss during cardiac surgery. One potential serious side effect of TXA is the occurrence of seizures. This association is described in case series 2 and several retrospective studies, [3] [4] [5] [6] [7] [8] [9] with most reports using high dose of TXA (up to 100 mg/kg). [3] [4] [5] [6] [7] [8] [9] This is the largest cohort of patients in which the effect of the dosage of TXA on the incidence of seizures has been studied. We found that patients receiving any dose of TXA have a higher incidence of seizures compared to patients in whom aprotinin or no antibibrinolytics were administered. Also, higher doses of TXA 1 are associated with a higher incidence of seizures compared to lower doses.
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Low dose TXA was associated with less postoperative seizures despite a higher plasma creatinine levels in these patients and the fact that more patients had DHCA in the lower dose TXA group. Patients undergoing open chamber cardiac surgery had a higher risk of seizures compared to CABG. Moreover, among patients who suffered from convulsive episodes, no difference in blood loss, number of transfusions, or any clinical or demographic data was found between patients receiving high or low dose TXA.
Post-operative seizure has been estimated to occur in about 0.5%-1% of cardiac patients. 12 The rate of seizures in the literature with (high dose) TXA surpasses this rate ranging from 1.97 to 7.6%. [2] [3] [4] [5] [6] [7] [8] [9] 12 In our study, patients receiving high dose TXA had a higher incidence of seizures than patients with lower doses TXA (1.55% vs 0.62%). The incidence of non-ischemic seizures in patients with low dose TXA was not different from patients receiving aprotinin. The incidence of seizure was higher in patient undergoing open chamber cardiac surgery suggesting that air and/or embolic materials facilitate the occurrence of seizures. This could be due to an increase in the blood-brain barrier permeability during and after open chamber surgeries. 2, 7, 13 The best strategy to decrease the incidence of seizures appears to be associated with the use of aprotinin, not using antifibrinolytic agents at all, or in the light of this study, low dose of TXA.
ɛ-Aminocaproic acid, another synthetic derivative of the amino acid lysine which is an alternative to TXA, has also been associated with postoperative seizures, although to a lower extent than TXA. 14 The proconvulsivant properties of tranexamic acid (TXA) likely result from a direct effects on the central nervous system, as application of TXA to the cortex or injection into the cisterna magna in experimenta animals causes generalized seizures. 14 There is also evidence for a doserelated toxicity of TXA when applied cortically in a rat model. 15 The decline in TXA levels in the cerebrospinal fluid appears to lag behind that in the blood after discontinuation of TXA infusion 12 , and seizure could arise due to persistently high concentrations of TXA in the brain during the early postoperative period. As reported previously, possible mechanism of TXAinduced seizures include direct cerebral ischemia secondary to decreases in regional or global cerebral blood flow 16 and blockage of inhibitory ƴ-aminobutiryc acid (GABA)-A receptors 17 which lead to the lowering of the depolarization threshold and enhanced excitotoxicity. It has been also reported that TXA competively inhibits glycine receptors, and this action contribute to seizures. 14 The association between TXA administration and postoperative seizures has been consistently reported in retrospective studies. [2] [3] [4] [5] [6] [7] [8] [9] However, most reports used higher dosage of TXA than those used in the present study (doses up to 100 mg/kg) [2] [3] [4] [5] [6] 8, 9 which may explain the higher incidence of NIS observed in those studies. [2] [3] [4] [5] [6] 8, 9, 12 In one of these studies, Koster et al. ) which is slightly lower than the dose used in our lower dose group.
They observed an incidence of convulsive seizures of 2.5%, which is higher than what we observed in our low dose TXA group (0.7%). However, they did not performed head CT scans to exclude ischemic lesions.
Previous studies have observed increased mortality rates, [4] [5] [6] [7] hospital stay 4, 6, 18 and intensive care unit length of stay, 7 duration of mechanical ventilatory support 7 rates of neurological complications, 6 rates of persistent atrial fibrillation and renal failure 19 in patients who experienced a convulsive seizure after cardiac surgery. The increased mortality rate was observed mostly for patients undergoing open heart surgery. 7, 18 A comprehensive review of medical records was undertaken only for patients who presented a convulsive seizure in the SICU, therefore we do not have demographic data, or clinical and laboratory results for the remaining of the patients without postoperative seizures. Consequently, we cannot compare patients with and without NIS for these parameters in our study. However, our data indicate that patients receiving TXA (low and high dose) who had seizures, did have a long ICU and hospital length of stay, and prolonged duration of mechanical ventilator support, which is consistent with previous reports. [4] [5] [6] [7] 18, 19 Patients experiencing postoperative seizures may also represent a sicker patient population with a greater prevalence of risk factors associated with postoperative morbidity and decreased survival as suggested by Goldstone et al 5 (higher age, diabetes mellitus, peripheral vascular disease, extensive aortic atheroslerosis or reoperation) 5 .
The conclusions of this study are affected by certain limitations. In this study, comparison of low to high dose is highly confounded with time, and any differences could be due to changes on practice other than a change in dose. In addition, adjustment for multiple comparison was not done in this exploratory study. Nevertheless, retrospective database analyses such as this one serve to identify opportunities for new randomized trials to test hypotheses in a scientifically rigorous fashion. The data were not collected from a database collected prospectively, and because it was impossible to make a comprehensive review of all 12195 patients, we cannot make comparison for demographic, comorbidities, pharmacologic, blood loss, blood products use, or other intraoperative or post-operative factors between patients experiencing seizures and those who did not. We observed a higher creatinine level on the day of seizure in the low dose TXA group. Because total body clearance of tranexamic acid approximates the glomerular filtration rate, 20 renal dysfunction would result in higher plasma concentration of tranexamic acid.
More patients underwent a deep hypothermic circulatory arrest (DHCA) during the surgery in the low dose regimen TXA, despite a lower incidence of seizures in this group. DHCA 4, 5 and renal dysfunction 21 have been found to be risk factors for seizures. These two factors may have increased the incidence of seizures in the low dose group. Finally, even if this study was not powered to detect differences in blood loss and red blood cells transfusions between low and high dose TXA patients with a seizure, several studies documented the efficacy of low dose TXA to decrease bleeding after CPB 3, 11, 22 and to inhibit fibrinolysis evaluated by thromboelastography during cardiac surgery. 23 In a randomized clinical trial, Horrow et al 22 reported that higher doses were unnecessary for reducing blood loss and that a 10/kg bolus followed by 1mg·kg (as used in the study of Horrow et al 22 ) in 569 patients scheduled for cardiac surgery, although not reducing the incidence of blood product transfusion, was found to be more effective to decrease transfusion needs, blood loss, and repeat surgery. No study directly compared the 2 doses of TXA used in our study for the effect on blood loss and transfusions, which should be validated in a prospective randomized trial.
Within the limitations of this retrospective study, we found that the administration of a lower dose of TXA 11 was associated with a reduction in the incidence of non-ischemic seizures when compared to a higher dose. 
